AKT is overexpressed in 50–70% of NSCLC tumors[6] and accordingly, AKT inhibitors MK-2206 and AZD5363 are currently undergoing clinical trials for lung cancer treatment. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.